Study of Coagulation Activation Markers and Pre Eclampsia (PRESTIGE)

U

University Hospital, Lille

Status

Completed

Conditions

Pre Eclampsia

Study type

Observational

Funder types

Other

Identifiers

NCT01261351
PHRC 2009/1910 (Other Grant/Funding Number)
2008_16/0921
2009-A00526-51 (Other Identifier)

Details and patient eligibility

About

The primary purpose of the trial is to evaluate coagulation activator markers in patients with pre eclampsia compared to control (normal pregnancy) and to correlate these markers with the severity of the pathology.

Full description

100 pre-eclamptic patients will be compared to 200 control patients (100 control matched on gestational age at inclusion and 100 control matched on delivery mode (section). Blood and urine samples will be collected at PE diagnosis, delivery and post partum. Two axes will be considered: Thrombography, or kinetic measurement of thrombin generation, by studying the coagulant profile according to Hemker's method in CAT System (Calibrated Automated Thrombogram) and by thromboelastogram in ROTEM technique (delocalized coagulation analyzer), in parallel to specific activation markers (thrombin-antithrombin complex, fibrin monomers). The balance of prostacyclin/thromboxane A2 by using ELISA method for urine samples and genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase's promoter CYP8A1).

Enrollment

300 patients

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years old
  • diagnosis of pre eclampsia

Exclusion criteria

  • multiple pregnancy
  • less than 18 year old

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems